Featured Oncology NewsU.S. Proposes Medicare Coverage For CAR-T Cancer Therapies
February 15, 2019
Bayer/Orion Showcase Results From Prostate Cancer Challenger
February 15, 2019
All Breast Cancer Patients Should Get Genetic Testing, Surgeons Say
February 15, 2019
Peer-Spectives is a new podcast series that is moderated by our editor-in-chief Robert Figlin, MD, and
features select thought-leaders covering the latest clinical developments in a wide range of cancer settings.
Moderated by:
Steven Spielberg Family
Chair in Hematology-Oncology
Cedars-Sinai Medical Center
We explore the scope of the escalating cost of cancer care, discuss the factors that contribute to the total cost of cancer care,
and provide resources to help us all understand the facts regarding the cost of cancer care.
Sponsored by:
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
FDA Rejects Immunomedics Breast Cancer Drug, Extending Long Regulatory Drought
Celgene, Sold For $74 Billion, Leaves A Legacy Of Chutzpah In Science And Drug Pricing
GSK Pays Up To $4.2 Billion For Merck KGaA Cancer Immunotherapy
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
Santa Monica, CA
Washington, DC
Orlando, FL
Atlanta, GA
Orlando, FL
Geneva, Switzerland
Denver, CO
Chicago, IL
RAI Amsterdam, The Netherlands
Lugano, Switzerland
San Francisco, CA
Buenos Aires, Argentina
Orlando, FL
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
Phase II Trial Shows Novel, Radiolabeled PSMA-Target...
February 13th 2019 by Tomasz M. Beer, MD, FACP
As contemporary hormonal agents are increasingly used earlier in prostate cancer, the need for nove...
Read More
FDA Alerts More Doctors Of Rare Cancer With Breast I...
February 11th 2019 by William McGivney, PhD
Breast Implants; Déjà Vu All Over Again Last week’s FDA warning regarding the association of...
Read More
The Patient Had Bone Cancer. The Diagnosis Arrived 2...
February 08th 2019 by H. Jack West, MD
"Paleo pathology" is cool. Cancer goes back to the Triassic period.
Read More
Bayer to Showcase New Data from its Growing Cancer P...
February 05th 2019 by Tomasz M. Beer, MD, FACP
Daralutamide would be the third agent with demonstrated efficacy in non-metastatic castration resis...
Read More
Janssen Announces ERLEADA® (apalutamide) Phase 3 TI...
January 31st 2019 by Tomasz M. Beer, MD, FACP
This study confirms one of the major trends in the field: that of intensifying upfront hormonal th...
Read More
Many Women Get Unnecessary Mammograms Before Breast ...
January 31st 2019 by Howard S. Hochster, MD
Good argument for tort reform. No surgeon wants to be in court for doing the wrong surgical proced...
Read More
OBR Green